PD-1抑制劑與PD-L1抑制劑有何不同? 相信是許多人的疑問 希望這篇能對您有些幫助
建議您先讀 腫瘤是如何抑制抗癌免疫反應的 和 什麼是CTLA4 ? 什麼是PD1? 會比較能夠理解這篇的內容
建議您先讀 腫瘤是如何抑制抗癌免疫反應的 和 什麼是CTLA4 ? 什麼是PD1? 會比較能夠理解這篇的內容
- Sep 08 Thu 2016 08:59
-
PDL1抑制劑與PD1抑制劑的不同處
- Jul 31 Sun 2016 22:12
-
Anti PD1藥品的安全性
- Jul 28 Thu 2016 03:18
-
腫瘤是如何抑制抗癌免疫反應的
- Oct 23 Sun 2016 11:57
-
FDA核准上市全球首支anti PDL1藥品Tecentriq (atezolizumab)治療4期肺腺癌
- Oct 12 Wed 2016 06:21
-
DC 細胞療法簡介
- Oct 07 Fri 2016 08:37
-
攻擊一個移動的目標: 瞭解和管理EGFR肺腺癌對TKI標靶藥品的抗藥性
Multiple randomized studies have demonstrated improved response rates, progression-free survival, and quality of life for treatment-naive, advanced-stage adenocarcinoma patients harboring sensitizing EGFR mutations when they are treated with tyrosine kinase inhibitor therapy, as compared with chemotherapy. Despite improved outcomes with these agents, the majority of patients will eventually develop resistance and subsequent clinical progression. Recently, there has been a firmer understanding of the molecular mechanisms of the resistance that develops as a consequence of treatment, most notably the identification of a second-site EGFR mutation, T790M. While this understanding can inform subsequent treatment decisions, disease progression can be heterogeneous, and there are several competing therapeutic options. Treatment decisions must consider this clinical heterogeneity, factoring in the pace of disease growth, lung cancer–related symptoms, and the potential presence of T790M mutations. Herein, we review the available literature addressing these competing strategies and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.
https://www.cancernetwork.com/oncology-journal/attacking-moving-target-understanding-resistance-and-managing-progression-egfr-positive-lung-cancer/page/0/1
https://www.cancernetwork.com/oncology-journal/attacking-moving-target-understanding-resistance-and-managing-progression-egfr-positive-lung-cancer/page/0/1
- Sep 04 Sun 2016 23:42
-
Nature雜誌: 腫瘤微環境PD-1/PD-L1與肺腺癌治療
During the last few decades, significant efforts of the interaction between immune system and immunotherapy to NSCLC have been acquired. Recent data have indicated that the lack of immunologic control is recognized as a hallmark of cancer currently. Programmed death-1 (PD-1) and its ligand PD-L1 play a key role in tumor immune escape and the formation of tumor microenvironment, closely related with tumor generation and development. Blockading the PD-1/PD-L1 pathway could reverse the tumor microenvironment and enhance the endogenous antitumor immune responses.
重點節錄
重點節錄
- Sep 03 Sat 2016 13:21
-
規律運動可以幫助雌激素健康代謝 降低乳癌罹患風險
鄭醫師的部落格
https://delightdetox1268.pixnet.net/blog/post/280267793-%E8%A6%8F%E5%BE%8B%E9%81%8B%E5%8B%95%E5%8F%AF%E4%BB%A5%E5%B9%AB%E5%8A%A9%E9%9B%8C%E6%BF%80%E7%B4%A0%E5%81%A5%E5%BA%B7%E4%BB%A3%E8%AC%9D%EF%BC%8C%E9%99%8D%E4%BD%8E%E4%B9%B3%E7%99%8C
https://delightdetox1268.pixnet.net/blog/post/280267793-%E8%A6%8F%E5%BE%8B%E9%81%8B%E5%8B%95%E5%8F%AF%E4%BB%A5%E5%B9%AB%E5%8A%A9%E9%9B%8C%E6%BF%80%E7%B4%A0%E5%81%A5%E5%BA%B7%E4%BB%A3%E8%AC%9D%EF%BC%8C%E9%99%8D%E4%BD%8E%E4%B9%B3%E7%99%8C
- Sep 02 Fri 2016 03:32
-
Atezolizumab 肺線癌第三期臨床實驗表現亮眼
Atezolizumab NSCLC第三期臨床實驗收ALK EGFR標靶化療失效的病人
全球共1225名病人 細節將在近期公布
https://www.roche.com/media/store/releases/med-cor-2016-09-01.htm
Atezolizumab NSCLC第三期臨床實驗顯示
全球共1225名病人 細節將在近期公布
https://www.roche.com/media/store/releases/med-cor-2016-09-01.htm
Atezolizumab NSCLC第三期臨床實驗顯示
- Aug 28 Sun 2016 11:34
-
Atezolizumab併用奈米太平洋紫杉醇治療三陰性乳癌數據
- Aug 27 Sat 2016 06:56
-
免疫治療的今、昔與未來
文 / 胡涵婷醫師 (血液與腫瘤內科)
筆者在美國重新接受住院醫師訓練時，親眼見證了癌症如何以野火燎原的攻勢，掠奪免疫機制被壓抑的病人的生命。我的訓練醫院內科副主任十多年前診斷早期大腸癌，開刀治癒了。後來，他因為一種罕見的膽道疾病造成肝衰竭，接受肝臟移植。雖然移植成功，他沉寂了超過十年的大腸癌，卻因為預防肝移植排斥所必須服用的免疫抑制劑，來勢洶洶地復發了。大腸癌細胞侵佔他的肺、骨頭以及甫移植的肝臟；短短三個月內，他就離開人世。這個活生生的例子告訴我們，人體有高度有效的控制癌細胞的免疫機制。當免疫機制崩潰或削弱時，癌症往往就一發不可收拾。
類似的故事實例與科學證據，比比皆是，一再說明了癌症與免疫機制的重要相關性。
筆者在美國重新接受住院醫師訓練時，親眼見證了癌症如何以野火燎原的攻勢，掠奪免疫機制被壓抑的病人的生命。我的訓練醫院內科副主任十多年前診斷早期大腸癌，開刀治癒了。後來，他因為一種罕見的膽道疾病造成肝衰竭，接受肝臟移植。雖然移植成功，他沉寂了超過十年的大腸癌，卻因為預防肝移植排斥所必須服用的免疫抑制劑，來勢洶洶地復發了。大腸癌細胞侵佔他的肺、骨頭以及甫移植的肝臟；短短三個月內，他就離開人世。這個活生生的例子告訴我們，人體有高度有效的控制癌細胞的免疫機制。當免疫機制崩潰或削弱時，癌症往往就一發不可收拾。
類似的故事實例與科學證據，比比皆是，一再說明了癌症與免疫機制的重要相關性。
